| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer, Inc., Eastern Point Road, Groton, CT 06340
1 To whom correspondence should be addressed. e-mail: h_james_harwood{at}groton.pfizer.com
A microsomal triglyceride transfer protein (MTP) inhibitor, CP-346086, was identified that inhibited both human and rodent MTP activity [concentration giving half-maximal inhibition (IC50) 2.0 nM]. In Hep-G2 cells, CP-346086 inhibited apolipoprotein B (apoB) and triglyceride secretion (IC50 2.6 nM) without affecting apoA-I secretion or lipid synthesis. When administered orally to rats or mice, CP-346086 lowered plasma triglycerides [dose giving 30% triglyceride lowering (ED30) 1.3 mg/kg] 2 h after a single dose. Coadministration with Tyloxapol demonstrated that triglyceride lowering was due to inhibition of hepatic and intestinal triglyceride secretion. A 2 week treatment with CP-346086 lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day. In these animals, MTP inhibition resulted in increased liver and intestinal triglycerides when CP-346086 was administered with food. When dosed away from meals, however, only hepatic triglycerides were increased. When administered as a single oral dose to healthy human volunteers, CP-346086 reduced plasma triglycerides and VLDL cholesterol dose dependently with ED50s of 10 mg and 3 mg, and maximal inhibition (100 mg) of 66% and 87% when measured 4 h after treatment. After a 2 week treatment (30 mg/day), CP-346086 reduced total and LDL cholesterol and triglycerides by 47%, 72%, and 75%, relative to either individual baselines or placebo, with little change in HDL cholesterol.
Together, these data support further evaluation of CP-346086 in hyperlipidemia.
Abbreviations: CETP, cholesterol ester transfer protein; CHD, coronary heart disease; ER, endoplasmic reticulum; MTP, microsomal triglyceride transfer protein
Supplementary key words microsomal triglyceride transfer protein • lipid transfer inhibition • very low density lipoprotein • low density lipoprotein • apolipoprotein B • apolipoprotein A-I • Hep-G2 cells
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Pan, F. N. Hussain, J. Iqbal, M. H. Feuerman, and M. M. Hussain Inhibiting Proteasomal Degradation of Microsomal Triglyceride Transfer Protein Prevents CCl4-induced Steatosis J. Biol. Chem., June 8, 2007; 282(23): 17078 - 17089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Hegele, M. Cuchel, and D. J. Rader Familial Hypercholesterolemia N. Engl. J. Med., April 26, 2007; 356(17): 1779 - 1780. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Huang, F. Sun, D. M. Owen, W. Li, Y. Chen, M. Gale Jr., and J. Ye From the Cover: Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins PNAS, April 3, 2007; 104(14): 5848 - 5853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lamant, F. Smih, R. Harmancey, P. Philip-Couderc, A. Pathak, J. Roncalli, M. Galinier, X. Collet, P. Massabuau, J.-M. Senard, et al. ApoO, a Novel Apolipoprotein, Is an Original Glycoprotein Up-regulated by Diabetes in Human Heart J. Biol. Chem., November 24, 2006; 281(47): 36289 - 36302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Spann, S. Kang, A. C. Li, A. Z. Chen, E. P. Newberry, N. O. Davidson, S. T. Y. Hui, and R. A. Davis Coordinate Transcriptional Repression of Liver Fatty Acid-binding Protein and Microsomal Triglyceride Transfer Protein Blocks Hepatic Very Low Density Lipoprotein Secretion without Hepatosteatosis J. Biol. Chem., November 3, 2006; 281(44): 33066 - 33077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J.P. Kastelein, M. K. Wedel, B. F. Baker, J. Su, J. D. Bradley, R. Z. Yu, E. Chuang, M. J. Graham, and R. M. Crooke Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B Circulation, October 17, 2006; 114(16): 1729 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mao, F. J. DeMayo, H. Li, L. Abu-Elheiga, Z. Gu, T. E. Shaikenov, P. Kordari, S. S. Chirala, W. C. Heird, and S. J. Wakil Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis PNAS, May 30, 2006; 103(22): 8552 - 8557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Rochester and C. E. Cooke The Changing Face of Dyslipidemia Therapies Journal of Pharmacy Practice, April 1, 2006; 19(2): 79 - 93. [Abstract] [PDF]
|
|
|
|
 |
|
 R. M. Crooke, M. J. Graham, K. M. Lemonidis, C. P. Whipple, S. Koo, and R. J. Perera An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis J. Lipid Res., May 1, 2005; 46(5): 872 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Cantor, T. de Bruin, N. Kono, S. Napier, A. van Nas, H. Allayee, and A. J. Lusis Quantitative Trait Loci for Apolipoprotein B, Cholesterol, and Triglycerides in Familial Combined Hyperlipidemia Pedigrees Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1935 - 1941. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
